Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1646 1647 1674
This examiner grants 61% of resolved cases
Andrea K Mccollum, in Tech Center 1600 and Art Unit 1646, has 618 resolved cases. Her allowance rate is 60.7 percent, which indicates a moderate likelihood of success for applicants. The median days to allowance is 1138, providing a standard benchmark for the expected duration of the prosecution process in this art unit.
The interview lift is 32.2 percent. This high lift suggests that interviews are a very effective strategy for increasing the likelihood of allowance beyond the 60.7 percent baseline. For practitioners, the 32.2 percent lift indicates that direct engagement with the examiner is one of the most productive ways to resolve rejections and move toward a grant. Given the 1138 days to allowance, applicants should prioritize interviews to maximize their chances of success and potentially navigate the prosecution timeline more effectively.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17732926 | BLOOD-BASED BIOMARKERS AND USE THEREOF FOR TREATING CANCER | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 18021641 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MEMBRANOUS NEPHROPATHY | Final Rejection | Mayo Foundation for Medical Education and Research |
| 17928850 | COMPOSITIONS AND METHODS FOR MODULATING DOPAMINE RECEPTOR ACTIVITY | Non-Final OA | The Regents of the University of California |
| 18481107 | SYNTHEKINE COMPOSITIONS AND METHODS OF USE | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18558729 | TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS USING ANTI-BAFFR ANTIBODIES | Non-Final OA | NOVARTIS AG |
| 18353133 | ANTI-IL-36R ANTIBODY FORMULATIONS | Non-Final OA | Boehringer Ingelheim International GmbH |
| 18530114 | STING LEVELS AS A BIOMARKER FOR CANCER IMMUNOTHERAPY | Non-Final OA | The Brigham and Women's Hospital, Inc. |
| 18278931 | TEST FOR MILD COGNITIVE IMPAIRMENT | Final Rejection | OSAKA UNIVERSITY |
| 17041006 | METHODS OF TREATING MINIMAL RESIDUAL CANCER | Final Rejection | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 18275602 | METHODS, ASSAYS AND COMPOSITIONS FOR MEASURING BRAIN DAMAGE OR HARM DURING SURGERY | Non-Final OA | National Cerebral and Cardiovascular Center |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy